test

PUBLIKATIONEN.

UNSERE
VERÖFFENTLICHUNGEN
IM ÜBERBLICK.

UNSERE PUBLIKATIONEN

Hier berichten wir über Publikationen unserer Mitglieder sowie unserer NOA-Verbundstudien.

UNSERE PUBLIKATIONEN

2022

Focal cavity radiotherapy after neurosurgical resection of brain metastases: sparing neurotoxicity without compromising locoregional control.

2022

Focal cavity radiotherapy after neurosurgical resection of brain metastases: sparing neurotoxicity without compromising locoregional control.

Klaus-Henning Kahl, Ehab Shiban, Susanne Gutser, Christoph J Maurer, Björn Sommer, Heiko Müller, Ina Konietzko, Ute Grossert, Ansgar Berlis, Tilman Janzen, Georg Stüben

Strahlenther Onkol . 2022 Sep 23. doi: 10.1007/s00066-022-02003-3

2021

A vaccine targeting mutant IDH1 in newly diagnosed glioma.

2021

A vaccine targeting mutant IDH1 in newly diagnosed glioma.

Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W.

Nature. 2021 Apr;592(7854):463-468

2020

Intraoperative radiotherapy with low energy X-rays after neurosurgical resection of brain metastases.

2020

Intraoperative radiotherapy with low energy X-rays after neurosurgical resection of brain metastases.

Klaus-Henning Kahl, Nikolaos Balagiannis, Michael Höck, Sabine Schill, Zoha Roushan, Ehab Shiban, Heiko Müller, Ute Grossert, Ina Konietzko, Maximilian-Niklas Bonk, Christoph Maurer, Ansgar Berlis, Volkmar Heidecke, Tilman Janzen, Georg Stüben

Augsburg University Medical Center experience – Strahlentherapie und Onkologie

2020

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study.

2020

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study.

Dirven L, Luerding R, Beier D, Bumes E, Reinert C, Seidel C, Bonsanto MM, Bremer M, Rieken S, Combs SE, Herrlinger U, Seliger C, Kuntze H, Mayer-Steinacker R, Dieing A, Bartels C, Schnell O, Weyerbrock A, Seidel S, Grauer O, Nadji-Ohl M, Paulsen F, Weller M, Wick W, Hau P.

J Neurooncol. 2020 May;148(1):117-130

2020

Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promotor-methylated malignant astrocytoma.

2020

Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promotor-methylated malignant astrocytoma.

Wick A,, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, Felsberg J, Weyerbrock A, Papsdorf K, Steinbach JP, Sabel M, Vesper J, Debus J, Meixensberger J, Ketter R, Hertler C, Mayer-Steinacker R, Weisang S, Bölting H, Reuss D, Reifenberger G, Sahm F, von Deimling A, Wick W; NOA-08 Study Group of the Neurooncology Working Group (NOA) of the German Cancer Society

Neuro Oncol. 2020;22: 1162 – 1172

2019

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trail

2019

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trail

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldliks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabei G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U.

J Neurooncol. 2019;144: 501 – 509

2019

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomised, open-label, phase 3 trial.

2019

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F et al.

Lancet 2019;393: 678 – 688

2019

N²M² (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

2019

N²M² (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M.

Neuro Oncol 2019;21: 95 – 105

2019

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.

2019

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.

Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Gold-brunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N

Lancet Oncol. 2019;20: 1444 – 1453

2018

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promotor-hypermethylation – the NCT Neuro Master Match (N²M²) pilot study.

2018

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promotor-hypermethylation – the NCT Neuro Master Match (N²M²) pilot study.

Pfaff E, Kessler T, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW, Wicke W, Sahm F.

Neuro Oncol 2018;20: 826 – 837